MX356295B - Análogos de péptido de la hormona de estimulación de alfa-melanocito. - Google Patents
Análogos de péptido de la hormona de estimulación de alfa-melanocito.Info
- Publication number
- MX356295B MX356295B MX2013012525A MX2013012525A MX356295B MX 356295 B MX356295 B MX 356295B MX 2013012525 A MX2013012525 A MX 2013012525A MX 2013012525 A MX2013012525 A MX 2013012525A MX 356295 B MX356295 B MX 356295B
- Authority
- MX
- Mexico
- Prior art keywords
- peptide analogs
- stimulating hormone
- alpha
- melanocyte stimulating
- analogs
- Prior art date
Links
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 title abstract 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 title abstract 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 abstract 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5637308P | 2008-05-27 | 2008-05-27 | |
| PCT/US2009/037809 WO2009151708A2 (en) | 2008-05-27 | 2009-03-20 | Peptide analogs of alpha-melanocyte stimulating hormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX356295B true MX356295B (es) | 2018-05-22 |
Family
ID=41278142
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012525A MX356295B (es) | 2008-05-27 | 2009-03-20 | Análogos de péptido de la hormona de estimulación de alfa-melanocito. |
| MX2010012990A MX2010012990A (es) | 2008-05-27 | 2009-03-20 | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. |
| MX2018006299A MX2018006299A (es) | 2008-05-27 | 2010-11-26 | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010012990A MX2010012990A (es) | 2008-05-27 | 2009-03-20 | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. |
| MX2018006299A MX2018006299A (es) | 2008-05-27 | 2010-11-26 | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8440793B2 (OSRAM) |
| EP (2) | EP2816055B1 (OSRAM) |
| JP (4) | JP5624027B2 (OSRAM) |
| KR (4) | KR101810110B1 (OSRAM) |
| CN (2) | CN107098957A (OSRAM) |
| AU (1) | AU2009258054B2 (OSRAM) |
| BR (1) | BRPI0912141A2 (OSRAM) |
| CA (2) | CA2726076C (OSRAM) |
| DK (2) | DK2297178T3 (OSRAM) |
| ES (2) | ES2715329T3 (OSRAM) |
| IL (3) | IL209369A (OSRAM) |
| MX (3) | MX356295B (OSRAM) |
| PT (2) | PT2816055T (OSRAM) |
| RU (1) | RU2496786C2 (OSRAM) |
| TR (1) | TR201903610T4 (OSRAM) |
| WO (1) | WO2009151708A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2816055B1 (en) | 2008-05-27 | 2018-12-19 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormons |
| CN101914138A (zh) * | 2010-07-13 | 2010-12-15 | 华东师范大学 | 一种用偶联剂制得的肝癌靶向肽-阿霉素及合成方法 |
| CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
| US9441013B2 (en) * | 2011-05-17 | 2016-09-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanocortin 1 receptor ligands and methods of use |
| WO2014081845A2 (en) | 2012-11-21 | 2014-05-30 | University Of Cincinnati | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor |
| WO2015067503A1 (en) * | 2013-11-07 | 2015-05-14 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of psoriasis |
| EP3212220A1 (en) * | 2014-10-28 | 2017-09-06 | Clinuvel AG | Inflammatory disease |
| EP3328372A4 (en) | 2015-07-28 | 2019-03-20 | University Of Iowa Research Foundation | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| SG10201506686WA (en) * | 2015-08-24 | 2017-03-30 | Agency Science Tech & Res | Conjugates |
| CN106905432B (zh) * | 2015-12-18 | 2018-12-21 | 兰州大学 | 一种α促黑素细胞激素的融合蛋白及其制备方法和应用 |
| US11732008B2 (en) | 2016-04-27 | 2023-08-22 | The Regents Of The University Of California | Preparation of functional homocysteine residues in polypeptides and peptides |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| US20220072092A1 (en) * | 2016-06-24 | 2022-03-10 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3523316B1 (en) * | 2016-10-04 | 2021-11-03 | DSM IP Assets B.V. | Melanocortin-1-receptor agonists |
| KR101957014B1 (ko) * | 2017-04-18 | 2019-06-20 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| BR112022005354A2 (pt) | 2019-09-23 | 2022-08-23 | Dds Res Inc | Composições de vesícula lipídica com agentes potencializadores de penetração |
| WO2021157973A1 (ko) * | 2020-02-07 | 2021-08-12 | 이화여자대학교 산학협력단 | 페길화된 ige-의존적 히스타민 방출인자(hrf) 결합 펩타이드 및 이의 용도 |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| RU2766340C1 (ru) * | 2021-02-10 | 2022-03-15 | Игорь Закванович Зайцев | Пептидный толерогенный компаунд |
| WO2022204305A2 (en) * | 2021-03-24 | 2022-09-29 | Glo Pharma, Inc. | Peptides and methods for reducing skin pigmentation |
| WO2023091689A1 (en) | 2021-11-19 | 2023-05-25 | University Of Iowa Research Foundation | Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5194425A (en) | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
| US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| US5618528A (en) | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
| US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| DE69738353T2 (de) * | 1996-07-12 | 2009-09-24 | Immunomedics, Inc. | Radiometall-bindende peptide analoge |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US20020193332A1 (en) * | 2001-02-12 | 2002-12-19 | Hedley Mary Lynne | Methods of treating bladder disorders |
| US6969702B2 (en) * | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| WO2005120588A2 (en) * | 2004-05-26 | 2005-12-22 | The Curators Of The University Of Missouri | Peptides delivered to cell nuclei |
| JP4734411B2 (ja) | 2005-07-08 | 2011-07-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンド |
| CA2648459A1 (en) * | 2006-04-05 | 2007-10-18 | The Regents Of The University Of California | Compositions and methods for the analysis and treatment of aids wasting syndrome and immune cell dysfunction |
| FR2914646A1 (fr) * | 2007-04-04 | 2008-10-10 | Neorphys Soc Par Actions Simpl | Analogues peptidiques des recepteurs des melanocortines |
| US8069129B2 (en) * | 2007-04-10 | 2011-11-29 | Ab Initio Technology Llc | Editing and compiling business rules |
| CN101302245B (zh) * | 2007-05-09 | 2011-11-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体四肽类激动剂及其制备方法和用途 |
| EP2816055B1 (en) | 2008-05-27 | 2018-12-19 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormons |
-
2009
- 2009-03-20 EP EP14178968.5A patent/EP2816055B1/en not_active Not-in-force
- 2009-03-20 US US12/408,560 patent/US8440793B2/en active Active
- 2009-03-20 KR KR1020167020183A patent/KR101810110B1/ko not_active Expired - Fee Related
- 2009-03-20 MX MX2013012525A patent/MX356295B/es unknown
- 2009-03-20 CA CA2726076A patent/CA2726076C/en not_active Expired - Fee Related
- 2009-03-20 AU AU2009258054A patent/AU2009258054B2/en not_active Ceased
- 2009-03-20 DK DK09763002.4T patent/DK2297178T3/da active
- 2009-03-20 PT PT14178968T patent/PT2816055T/pt unknown
- 2009-03-20 KR KR1020187030624A patent/KR20180118250A/ko not_active Ceased
- 2009-03-20 CN CN201611160601.4A patent/CN107098957A/zh active Pending
- 2009-03-20 WO PCT/US2009/037809 patent/WO2009151708A2/en not_active Ceased
- 2009-03-20 EP EP09763002.4A patent/EP2297178B1/en not_active Not-in-force
- 2009-03-20 TR TR2019/03610T patent/TR201903610T4/tr unknown
- 2009-03-20 ES ES14178968T patent/ES2715329T3/es active Active
- 2009-03-20 RU RU2010153217/04A patent/RU2496786C2/ru not_active IP Right Cessation
- 2009-03-20 CA CA2998948A patent/CA2998948A1/en not_active Abandoned
- 2009-03-20 DK DK14178968.5T patent/DK2816055T3/en active
- 2009-03-20 KR KR1020107029335A patent/KR101666631B1/ko not_active Expired - Fee Related
- 2009-03-20 KR KR1020177023883A patent/KR20170102050A/ko not_active Ceased
- 2009-03-20 BR BRPI0912141A patent/BRPI0912141A2/pt not_active IP Right Cessation
- 2009-03-20 MX MX2010012990A patent/MX2010012990A/es active IP Right Grant
- 2009-03-20 JP JP2011511661A patent/JP5624027B2/ja not_active Expired - Fee Related
- 2009-03-20 CN CN200980120892.6A patent/CN102143970B/zh not_active Expired - Fee Related
- 2009-03-20 ES ES09763002.4T patent/ES2492670T3/es active Active
- 2009-03-20 PT PT97630024T patent/PT2297178E/pt unknown
-
2010
- 2010-11-17 IL IL209369A patent/IL209369A/en not_active IP Right Cessation
- 2010-11-26 MX MX2018006299A patent/MX2018006299A/es unknown
-
2013
- 2013-05-08 US US13/890,039 patent/US9115174B2/en active Active
-
2014
- 2014-07-24 JP JP2014150428A patent/JP6170019B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/830,572 patent/US9738698B2/en active Active
-
2016
- 2016-05-29 IL IL245906A patent/IL245906A0/en unknown
-
2017
- 2017-01-05 JP JP2017000343A patent/JP6585099B2/ja not_active Expired - Fee Related
- 2017-05-01 IL IL252058A patent/IL252058A0/en unknown
- 2017-07-10 US US15/645,974 patent/US10385108B2/en active Active
-
2019
- 2019-02-04 JP JP2019017752A patent/JP2019065053A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX356295B (es) | Análogos de péptido de la hormona de estimulación de alfa-melanocito. | |
| WO2011054001A3 (en) | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use | |
| EA201390194A1 (ru) | Улучшенный рекомбинантный фолликул-стимулирующий гормон человека | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| MX2009005849A (es) | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. | |
| MY153976A (en) | Lh liquid formulations | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
| MX2010005451A (es) | Sistema para la liberacion en una celula positiva para xcr1 y usos de este. | |
| MA32568B1 (fr) | Formulations pharmaceutiques contenant des ligands de recepteur de dopamine | |
| AR056806A1 (es) | Moleculas quimericas de anticuerpo rankl- pth/ pthrp | |
| CO6280470A2 (es) | Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina | |
| PH12012500895A1 (en) | Method for treating heart failure with stresscopin-like peptides | |
| CY1115961T1 (el) | Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) | |
| WO2007093373A3 (en) | Branched multimeric peptides for tumor diagnosis and therapy | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| JP2010537623A5 (OSRAM) | ||
| MX2011007108A (es) | Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos. | |
| TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
| PE20080674A1 (es) | Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico | |
| MD3885F1 (en) | Method for polyparasitosis complex treatment to cattle | |
| EP2370454A4 (en) | WDRPUH EPITOP PEPTIDES AND VACCINES CONTAINING THEM | |
| TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system |